2.4. Drug Administration
STERILE
Enrolled patients received EG-Mirotin once per day (3 mg in 1.5 mL of sterile saline) for 5 days with an additional follow-up period of approximately 7 weeks (8 weeks in total: screening (V1), treatment period (V2–V6), follow-up period (V7–V9)). End of study was approximately 8 ± 1 weeks (57 ± 7 days) after the first dose.